GINMU >
01 奈良県立医科大学 >
011 医学部 >
0112 紀要 >
01121 Journal of Nara Medical Association >
Vol.67 No.4,5,6 >
このアイテムの引用には次の識別子を使用してください:
http://hdl.handle.net/10564/3356
|
タイトル: | Role of CD10 in the Metastasis of Colorectal Cancer to the Liver. |
著者: | Fujii, Kiyomu Ohmori, Hitoshi Fujiwara-Tani, Rina Luo, Yi Nishiguchi, Yukiko Kishi, Shingo Sasaki, Takamitsu Kuniyasu, Hiroki |
キーワード: | CD10 Met-enkephalin opioid receptor EGFR |
発行日: | 2016年12月31日 |
出版者: | 奈良医学会 奈良県立医科大学 |
引用: | Journal of Nara Medical Association Vol.67 No.4,5,6 p.41-50 (2016.12) |
抄録: | CD10 is a widely expressed endopeptidase that is present in human colorectal cancer (CRC), which shows a high frequency of liver metastasis. CD10 expression in CRC cells is associated with liver metastasis in rodent models, and CD10 expression enhances the phosphorylation of epidermal growth factor (EGF) receptor (EGFR) and extracellular signalregulated kinase (ERK) l/2. Met-enkephalin (MENK), a CD10 substrate, activates its specific receptor δ-opioid receptor (DOR), which is expressed in CRCs. DOR is a partial agonist of ERK1/2, which suppresses EGF-induced phosphorylation of EGFR and ERK1/2. CD10 retains EGF-induced EGFR activation by degrading MENK. Paradoxically, CRCs express MENK at a high frequency. Since MENK suppresses T lymphocytes, CD10-expressing CRCs can escape from T-cell immunity without exhibiting auto-inhibition. CD10 is strongly associated with the metastasis of CRCs to the liver via an immunosuppressive mechanism. Additionally, CD10 may be an excellent serum marker for liver metastasis in patients with CRC and could represent a potential molecular target for antimetastatic treatment in patients with CRC. |
URI: | http://hdl.handle.net/10564/3356 |
ISSN: | 13450069 |
出現コレクション: | Vol.67 No.4,5,6
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|